Posts

Posted on

Costa Cruises Celebrates Float-Out Ceremony For Costa Toscana; Italian Cruise Line’s New LNG Ship Will Be Delivered In December

Costa Toscana, celebrating the excellence of Tuscany, is the third ship of the Costa Group powered by liquefied natural gas, the marine industry’s most advanced fuel technology available for reducing emissions.

Built at the Meyer shipyard in Turku, Costa Toscana will enter service in December 2021 in Brazil.

PR Newswire

GENOA, Italy and TURKU, Finland, Jan. 15, 2021 /PRNewswire/ — Costa Cruises, the Italian company of Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), the world’s largest cruise company, today celebrated the float-out ceremony of the new flagship Costa Toscana at the Meyer shipyard inTurku, Finland.

Costa Toscana, as her sister ship Costa Smeralda, is powered by liquefied natural gas (LNG), the marine industry’s most advanced fuel technology currently available for reducing emissions, both at sea and during port calls. Costa Group, which includes Costa Cruises, Germany-based AIDA Cruises and Costa Asia, was the first in the cruise industry worldwide to introduce this technology, having ordered five new LNG-powered ships, two of which, Costa Smeralda and AIDAnova, have already entered service. They are part of an expansion plan that includes seven new ships to be delivered to Costa Group by 2023, for a total investment of more than six billion euros.

During the float-out ceremony, Costa Toscana officially touched the sea for the first time, with the flooding of the basin where she has been built in recent months. She will enter service in December 2021, once the interior fittings have been completed.


Mario Zanetti, chief commercial officer of Costa Cruises and president of Costa Group Asia, commented: “Despite the current challenging scenario, Costa Group is confirming its investment in fleet expansion. We are confident in the recovery of our industry, and we are excited about the arrival of new ships like Costa Toscana, which embodies the elements we want to focus on for the future. First of all, it is an excellent and innovative ship, attractive for new customers, which is going to be fundamental, especially when people will be able to freely travel again and will have a great desire for holidays. Looking beyond the pandemic, the second element we are focusing on is to complete the transformation of our fleet and operations into a sustainable model. In addition to LNG technology, we are developing other innovative solutions, such as shore power and batteries, as we continue to work towards achieving zero emissions over time.”

“The float-out is always a very special occasion for us shipbuilders, as the ship is finally set to her natural environment. As this is also the start of the final stage of shipbuilding, all the exciting colors, venues and features will start taking their final form. In the coming months she will be finalized at the pier and then tested and commissioned in the autumn for delivery,” CEO of Meyer Turku, Tim Meyer, said.

Costa Toscana has been designed to be a traveling “smart city,” where sustainable solutions and circular economy concepts are applied to reduce environmental impact. Thanks to the use of LNG, it will be possible to virtually eliminate emissions of sulfur dioxide (zero emissions) and particulate matter into the atmosphere (95-100% reduction), while also significantly lowering emissions of nitrogen oxides (direct reduction of 85%) and CO2 (up to 20%). On board, special desalinisation plants will process seawater directly to meet daily water supply requirements, and energy consumption will be reduced to a minimum thanks to an intelligent energy efficiency system. In addition, 100% separate collection and recycling of materials such as plastic, paper, glass and aluminum will be carried out on board, as part of an integrated approach aimed at supporting circular economy projects.

The new flagship is a tribute to Tuscany, the result of an extraordinarily creative project, curated by Adam D. Tihany, designed to enhance and bring to life in a single location reflecting the best of this wonderful Italian region, which gives its name to the ship, its decks and main public areas.

Tihany has worked with an international pool of prestigious architectural firms – Dordoni Architetti, Jeffrey Beers International and Partner Ship Design – to design the different areas of the ship. All the furnishings, lighting, fabrics and accessories are made in Italy, whether standard produced or designed specifically for the new flagship by 15 partners who are highly representative of Italian excellence.

The facilities on board will fit perfectly into this extraordinary setting: from the Solemio Spa to the areas dedicated to entertainment; from the themed bars, in collaboration with major Italian brands, to the 16 restaurants and areas dedicated to the “food experience,” including the restaurant dedicated to families with children, and the LAB Restaurant, where you can try your cooking skills under the guidance of Costa’s chefs.

The “heart” of the new flagship will be the “Colosseo,” a space in the centre of the ship spread over three decks, dedicated to the best shows. The big screens, positioned both on the walls and on the dome, offer the possibility of creating a different story in every port of call and in every moment of the holiday.

Also not to be missed is the large stairway on three decks facing astern: the ideal place for entertaining guests, both young and old, with an open-air balcony on the top deck featuring a crystal floor that lets you experience the thrill of “flying” over the sea.

To relax and enjoy the sun there will be four swimming pools, one of which will be indoors with salt water, with a new beach club, which will recreate the atmosphere of a real bathing establishment.

Comfortable and elegant, the more than 2,600 cabins on board perfectly reflect Italian style and taste. The “Sea Terrace” cabins will offer a beautiful veranda where you can have breakfast, sip an aperitif or simply enjoy the view.

Costa Toscana will make its debut in Brazil in the 2021-22 season. In particular, the inaugural New Year’s Eve cruise will depart from Santos on Dec. 26, 2021, with a week-long itinerary visiting Salvador and Ilhéus, and returning to Santos on Jan. 2, 2022. From Jan. 2 to April 10, 2022, Costa Toscana will offer another 15 cruises with the same itinerary, embarking in Santos and Salvador. The 15 cruises also include the Carnival and Easter departures, which will be the ship’s last cruise before the Brazil–Italy crossing, departing from Santos on April 17, 2022.

 

Cision View original content:http://www.prnewswire.com/news-releases/costa-cruises-celebrates-float-out-ceremony-for-costa-toscana-italian-cruise-lines-new-lng-ship-will-be-delivered-in-december-301209166.html

SOURCE Costa Cruises

Posted on

Pyxis Tankers to Present at NobleCon 17 Investor Conference

MAROUSSI, GREECE – January 15, 2020 – Pyxis Tankers Inc. (NASDAQ: PXS), (the “Company” or “Pyxis Tankers”), a growth – orientated pure play product tanker company, today announced that its CEO, Mr. Eddie Valentis will present on Wednesday, January 20th at Noble Capital Markets’ Seventeen Annual Investor Virtual Conference at 1:30 pm EST. The conference is virtual and there is no cost, obligation nor restriction to investors to attend: www.noblecon17.com

A high-definition, video webcast of the presentation will be available on Thursday, January 21th on the Company’s website, http://www.pyxistankers.com, and as part of a complete catalog of presentations available at Noble Capital Markets’ website: www.nobleconference.com  and on its investor portal, Channelchek: www.channelchek.com. The webcast and presentation will be archived on Noble website for 90 days following its event and the Company’s website.

Webcast: https://noble.mediasite.com/Mediasite/Play/b2ce0a0d3d1749819954504100ebc7d31d

About Pyxis Tankers Inc.

We own a modern fleet of five tankers engaged in seaborne transportation of refined petroleum products and other bulk liquids. We are focused on growing our fleet of medium range product tankers, which provide operational flexibility and enhanced earnings potential due to their “eco” features and modifications. We are positioned to opportunistically expand and maximize our fleet due to competitive cost structure, strong customer relationships and an experienced management team, whose interests are aligned with those of its shareholders.

Company

Pyxis Tankers Inc.
59 K. Karamanli Street

Maroussi, 15125 Greece
[email protected]

Visit our website at www.pyxistankers.com

Company Contact

Henry Williams
Chief Financial Officer
Tel: +30 (210) 638 0200 / +1 (516) 455-0106
Email: [email protected]

Source: Pyxis Tankers Inc.



Posted on

Primoris Services Corporation Completes Future Infrastructure Acquisition

DALLAS, Jan. 15, 2021 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”), a leading provider of specialty contracting services in North America, announced today that it has closed its acquisition of Future Infrastructure Holdings, LLC (“Future Infrastructure” or “FIH”) in an all-cash transaction valued at $620 million. The transaction directly aligns with Primoris’ strategy to grow in large, higher growth, higher margin markets, and expands the Company’s utility services capabilities.

Future Infrastructure is a provider of non-discretionary maintenance, repair, upgrade, and installation services to the telecommunication, regulated gas utility, and infrastructure markets. As a result of the acquisition, Future Infrastructure will be integrated into the Company’s Utilities Segment, furthering Primoris’ strategic plan to expand its service lines, enter new markets, and grow the Company’s MSA revenue base.

Tom McCormick, Primoris’ President and Chief Executive Officer, said, “The addition of Future Infrastructure marks the completion of a strategic goal for Primoris, but also marks the beginning of a new stage in our strategic journey to create the Company we believe we can be – together. With values and cultures that are already aligned in many ways, we are confident that this combination will lead us to even greater successes.”

Notice of Issuance of Inducement Grants

In connection with the closing of Future Infrastructure, Primoris granted stock-based compensation to 16 employees of FIH and its subsidiaries representing an aggregate of 1,213,032 shares of common stock (the “Inducement Grants”). The Inducement Grants consisted of the following types of equity awards: (i) stock purchase rights representing 1,086,752 shares of common stock purchased at a 15 percent discount, subject to an 18-month holding period and (ii) restricted stock units representing the right to receive up to 126,280 shares of common stock, subject to time-vesting on the third anniversary of the grant date. The Inducement Grants have been approved by the Compensation Committee of the Board of Directors. The Inducement Grants will be issued outside of Primoris’ shareholder-approved equity incentive plan as an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4).

ABOUT PRIMORIS

Founded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating throughout the United States and Canada. Primoris provides a wide range of specialty construction services, fabrication, maintenance, and engineering services to a diversified base of customers. Additional information on Primoris is available at www.prim.com.

FORWARD LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of the federal securities laws. These statements give the current expectations of the Company’s management. Words such as “could,” “will,” “may,” “assume,” “forecast,” “strategy,” “guidance,” “outlook,” “target,” “expect,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” or “project” and similar expressions are used to identify forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements contained in this release include the Company’s expectations regarding the consummation of the transactions described herein.

Forward-looking statements can be affected by assumptions used or known or unknown risks or uncertainties. Consequently, no forward-looking statements can be guaranteed and actual results may differ materially and adversely from those reflected in the forward-looking statements. Factors that could cause actual results to differ materially from those indicated in the forward-looking statements include, among other things, (a) the risks and uncertainties disclosed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and from time to time in our other filings with the Securities and Exchange Commission (“SEC”) and (b) the following risks inherent in the transactions (in addition to others described elsewhere in this document and in the subsequent filings with the SEC): failure to obtain regulatory approval necessary to consummate the transactions or to obtain regulatory approvals on favorable terms; failure to secure financing arrangements on favorable terms to consummate the transactions;  delays in consummating the transactions or the failure to consummate the transactions; the possibility of business disruption during the pendency of or following the transactions; the risk that management time may be diverted on transaction-related issues; the reaction of customers and other third parties to the proposed transactions; and other events or circumstances that could adversely impact the completion of the transactions, including the ongoing COVID-19 pandemic and other industry, political, competitive or economic conditions outside of our control.

Forward-looking statements speak only as of the date made and can be affected by assumptions the Company might make or by known or unknown risk and uncertainties. Many factors mentioned in this release and in the Company’s annual and quarterly reports will be important in determining future results. Consequently, you are urged to consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of forward-looking statements, as the Company cannot assure you that the Company’s expectations or forecasts expressed in such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For additional information, contact:

Brook Wootton
Vice President, Investor Relations
Primoris Services Corporation, 214-545-6773
[email protected]



Posted on

Enstar Announces Reinsurance Transaction With ProSight

HAMILTON, Bermuda, Jan. 15, 2021 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) announced today that one of its wholly owned subsidiaries has entered into an agreement with subsidiaries of ProSight Global, Inc. (“ProSight”) to provide reinsurance relating to 2019 and prior year business.

The reinsurance will comprise a ground up loss portfolio transfer of ProSight’s discontinued workers’ compensation and excess workers’ compensation lines of business and an adverse development cover on ProSight’s diversified mix of general liability classes of business. In the transaction, ProSight will cede net loss reserves of approximately $500 million and Enstar’s subsidiary will provide additional aggregate limit of $250 million.  

The transaction is subject to the closing of a broader strategic transaction announced by ProSight today and remains subject to regulatory approval and other closing conditions.

About Enstar

Enstar is a NASDAQ-listed leading global insurance group that offers innovative capital release solutions through its network of group companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia, and other international locations. A market leader in completing legacy acquisitions, Enstar has acquired over 100 companies and portfolios since its formation in 2001. For further information about Enstar, see www.enstargroup.com.


Cautionary Statement

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the intent, belief or current expectations of Enstar and its management team. Investors are cautioned that any such forward-looking statements speak only as of the date they are made, are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. In particular, Enstar may not be able to complete the proposed transaction on the terms summarized above or other acceptable terms, or at all, due to a number of factors, including but not limited to the failure to obtain regulatory approvals or to satisfy other closing conditions. In addition, the evolving COVID-19 pandemic has caused significant economic and financial turmoil globally, as well as uncertainty and volatility in the financial markets. Due to the global uncertainty, we are unable to predict the longer-term effects of the pandemic on our business at this time. Important risk factors regarding Enstar can be found under the heading “Risk Factors” in Enstar’s Form 10-K for the year ended December 31, 2019 and in Enstar’s Form 10-Q for the three and nine months ended September 30, 2020 and are incorporated herein by reference. Furthermore, Enstar undertakes no obligation to update any written or oral forward-looking statements or publicly announce any updates or revisions to any of the forward-looking statements contained herein, to reflect any change in its expectations with regard thereto or any change in events, conditions, circumstances or assumptions underlying such statements, except as required by law.

Contact:  Enstar Communications
Telephone:  +1 (441) 292-3645



Posted on

Ms. Opal Lee To Be Recognized By International Peace Honors And Visit Fort Worth, Has Been Named An Unsung Hero By StoryTerrace

FORT WORTH, TX, Jan. 15, 2021 (GLOBE NEWSWIRE) — Today Unity Unlimited announces that social impact leader and ‘Grandmother of Juneteenth,’ Ms. Opal Lee is the recipient of three prestigious awards.

The inaugural International Peace Honors, which celebrate the most prominent world leaders and change-agents of our time, whose common goal is to build a more just and equitable future, will honor Ms. Opal during a live ceremony at 8:00pm ET / 5:00pm PT on January 17. She joins an esteemed group of people, with fellow honorees including Dr. Anthony Fauci, Opal Tometi, the co-founder of Black Lives Matter, singer-songwriter and Human Rights Activist, Ricky Martin and more.

Visit Fort Worth, the tourism marketing organization for the nation’s 13th largest city, will present Ms. Opal with their coveted annual Hospitality Award at the organization’s socially distanced annual meeting and breakfast on February 5. She has been selected for her efforts to make Fort Worth a more welcoming community. Previous honorees include Fort Worth’s Mayor Betsy Price, singer and songwriter Leon Bridges, and Holt Hickman, who revived the city’s Stockyards district.

In more exciting news, memoir writing service, StoryTerrace, has chosen Ms. Opal as the Leading Hero in their search for the Unsung Heroes of COVID-19 in 2020. The StoryTerrace Unsung Heroes of COVID-19 initiative sought to find ordinary people doing extraordinary things during the pandemic. Ms. Opal’s entry – submitted by a dear friend unbeknownst to her – was selected from nearly 500 applicants. She and 24 others have been recognized; however, Ms. Opal was named the Leading Hero of the campaign. 

Her story is being included in a compilation book of the top 25 Unsung Heroes of COVID-19, due to be released later this year, and a portion of the proceeds will be donated to Unity Unlimited.

Ms. Opal said: “Wow! I can’t believe I’m being recognized alongside so many amazing young people. Having lived in Fort Worth since I was 10, I love my city and helping people have a better life here is something I try to do every day, so thank you, Visit Fort Worth for your ongoing support.

“I’m incredibly grateful to StoryTerrace for the opportunity to tell my story and educate people around the world about the importance of making Juneteenth a national holiday. I truly believe Juneteenth is a unifier and can be the bridge that can bring people together to talk about the hard issues facing our country.”

###

Watch the International Peace Honors live stream here.

Watch Ms.Opal’s StoryTerrace Unsung Hero reveal here.

Sign Ms.Opal’s petition to make Juneteenth a national holiday here.



About Ms. Opal Lee
Ms. Opal is the oldest living board member of the National Juneteenth Observance Foundation  (NJOF) that was founded and led by the late Dr. Ronald Myers, Sr., whose initiative is for Juneteenth  to become a national holiday. To bring awareness to the cause, she started her Opal’s Walk 2 DC campaign in 2016, where she walked 2.5 miles to symbolize the 2.5 years that it took for slaves in Texas to know that they were free. Ms. Opal launched a petition to make Juneteenth a national  holiday on Change.org, and in September 2020 delivered the 1.5 million signatures it had received to  Congress. Ms.Opal believes that freedom should be celebrated from the 19th of June to the 4th of  July. Visit Ms. Opal’s EPK for more.

About Unity Unlimited, Inc.
Unity Unlimited, Inc. is a non-profit organization whose main mission is providing educational activities and resources to people, young and old, to foster unity and harmony within the community, the city, the state, the nation and the world regardless of race, culture or denomination. For more information visit: www.unityunlimited.org/

Attachment 



Brea Carter
[INVNT GROUP]
+1 917 633 6171
[email protected]

Posted on

VelocityEHS Helps EHS Professionals Comply with OSHA’s February 1 Recordkeeping Standard Deadline

CHICAGO, Jan. 15, 2021 (GLOBE NEWSWIRE) — VelocityEHS, the global leader in cloud-based environment, health, safety (EHS) and sustainability solutions, is providing safety and HR professionals with resources to help them comply with OSHA’s upcoming Recordkeeping Standard deadline. Employers covered by the standard must complete and sign Form 300A and post the summary of serious injuries and illnesses from the previous year in a location that is clearly visible to all employees and new applicants from February 1 to April 30. Additionally, those establishments covered by OSHA’s electronic reporting rule must submit electronic files containing 300A data to OSHA via the Injury Tracking Application (ITA) by March 2. VelocityEHS’ award-winning software makes it fast and easy to log and file forms, while its expert-led resources assist safety professionals with understanding their reporting obligations to help them stay in compliance.

For this year’s deadline, many safety professionals are seeking guidance on reporting COVID-19 illnesses. Under OSHA’s recordkeeping requirements, COVID-19 is a recordable illness and employers are required to record cases of COVID-19, if:

  • The case is a confirmed case of COVID-19, as defined by the Centers for Disease Control and Prevention (CDC);
  • The case is work-related as defined by 29 CFR 1904.5; and
  • The case involves one or more of the general recording criteria set forth in 29 CFR 1904.7.

While this does not mean employers must record every COVID-19 case that appears in their workplace, they must record it on the OSHA 300 log when evidence of it being work-related appears. OSHA has stated that, due to the nature of the disease and ubiquity of community spread, it might be difficult to determine whether a COVID-19 illness is work-related, especially when an employee has experienced potential exposure both in and out of the workplace. In light of this, the agency is exercising enforcement discretion to assess employers’ efforts in making work-related determinations, assessing the information available to the employer and the reasonableness of their determination.

Employers seeking additional guidance with reporting obligations are encouraged to watch VelocityEHS’ on-demand webinar, “OSHA’s Recordkeeping Standard: Your Guide to Compliance.” Offered to the public at no cost, the webinar provides a comprehensive review of recent updates to the Recordkeeping Standard, current Electronic Reporting applicability and due dates, as well as best practices for ensuring compliance. Also available from VelocityEHS is its OSHA Recordkeeping Infographic, which helps EHS professionals quickly and easily determine which workplace incidents are OSHA recordable or reportable, what next steps need to be taken, and when.

“Complications around OSHA’s Recordkeeping reporting deadline often occur when employers have not kept consistent records of workplace injuries and illnesses throughout the year,” said John Damgaard, CEO of VelocityEHS. “Digital recordkeeping streamlines the process, reduces paperwork and ensures your obligations are met. More importantly, VelocityEHS helps you get beyond just tracking workplace injuries and illnesses, and empowers you to actively prevent incidents from occurring in the first place.”

VelocityEHS’ easy-to-use Incident Management software provides a more comprehensive way to record detailed incident information, and generate regulatory forms and files for electronic submission. The software streamlines the reporting process by enabling users to generate the injury and illness summaries they are required to post on-site each February, and helps establishments subject to electronic reporting requirements to easily submit their 300A to OSHA’s ITA electronically. In addition, the award-winning VelocityEHS mobile app makes it easier to manage workplace incidents by engaging front-line workers to instantly report accidents, near misses and hazards as they occur – with or without internet connectivity – via a smartphone or tablet device for faster, more detailed and accurate accounts of reportable incidents.

For more information about VelocityEHS and its full suite of award-winning EHS products and services, visit www.EHS.com.

About VelocityEHS
Trusted by more than 19,000 customers worldwide, VelocityEHS helps you reach your EHS goals faster with quick implementations, affordable solutions and unparalleled customer support. We deliver a comprehensive cloud-based environment, health and safety (EHS) software platform. Our easy-to-use software applications are designed based on industry best-practice principles to help you solve complex business challenges in simple ways. Recognized by the EHS industry’s top independent analysts, including leading scores in the Verdantix 2019 Green Quadrant Analysis, VelocityEHS is the global leader in cloud EHS software solutions.

VelocityEHS is headquartered in Chicago, Illinois, with locations in Ann Arbor, Michigan; Tampa, Florida; Oakville, Ontario; London, England; and Perth, Western Australia. For more information, visit www.EHS.com. 

Media Contact

Betsy Utley-Marin
312.881.2307
[email protected]  



Posted on

Wells Fargo Reports Fourth Quarter 2020 Financial Results

Wells Fargo Reports Fourth Quarter 2020 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–
Wells Fargo & Company (NYSE: WFC) has released its fourth quarter 2020 financial results. The financial results are available online at https://www.wellsfargo.com/about/investor-relations/quarterly-earnings/ and on a Form 8-K filed by the Company with the Securities and Exchange Commission (SEC) on January 15, 2021 and available on the SEC’s website at www.sec.gov.

Conference Call

The Company will host a live conference call on Friday, January 15, at 10 a.m. ET. You may listen to the call by dialing 866-872-5161 (U.S. and Canada) or 440-424-4922 (International). The call will also be available online at https://www.wellsfargo.com/about/investor-relations/quarterly-earnings/ and https://engage.vevent.com/rt/wells_fargo_ao/index.jsp?seid=527.

A replay of the conference call will be available beginning at approximately 2 p.m. ET on January 15 through Friday, January 29. Please dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (International) and enter Conference ID: 6849835. The replay will also be available online at https://www.wellsfargo.com/about/investor-relations/quarterly-earnings/ and https://engage.vevent.com/rt/wells_fargo_ao/index.jsp?seid=527.

About Wells Fargo

Wells Fargo & Company is a leading financial services company that has approximately $1.9 trillion in assets and proudly serves one in three U.S. households and more than 10% of all middle market companies in the U.S. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer Banking and Lending; Commercial Banking; Corporate and Investment Banking; and Wealth and Investment Management. Wells Fargo ranked No. 30 on Fortune’s 2020 rankings of America’s largest corporations. In the communities we serve, the company focuses its social impact on building a sustainable, inclusive future for all by supporting housing affordability, small business growth, financial health and a low-carbon economy.

News Release Category: WF-CF

Media

Peter Gilchrist, 704-715-3213

[email protected]

Investor Relations

John Campbell, 415-396-0523

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Chipotle And The Shawn Mendes Foundation Launch Wonder Grants To Support Young Innovators In Sustainability

PR Newswire

The Shawn Mendes Bowl added to menu for a limited time to support youth change makers

NEWPORT BEACH, Calif., Jan. 15, 2021 /PRNewswire/ — Chipotle Mexican Grill (NYSE: CMG) today announced it is partnering with Shawn Mendes and the Shawn Mendes Foundation to launch “Wonder Grants” supporting young innovators in sustainability, as well as a “Shawn Mendes Bowl” on the Chipotle app and Chipotle.com for a limited time in the U.S. and Canada. 

Bringing Purpose to the Menu
For every Shawn Mendes Bowl sold, Chipotle will donate $1 toward the Shawn Mendes Foundation in support of changemakers.1 The new digital menu item features Cilantro-Lime Cauliflower Rice, the brand’s latest menu innovation that was launched earlier this month.

  • Shawn Mendes Bowl: Cilantro-Lime Cauliflower Rice, black beans, chicken, roasted chili-corn salsa, romaine lettuce, and guac

This marks the first time Chipotle has launched a philanthropic entrée on its menu.  

Wonder Grants
Chipotle and Shawn Mendes are also awarding “Wonder Grants” to young activists focused on sustainability. “Wonder Grants” are designed to help young changemakers with big ideas but insufficient resources to launch or complete innovative projects across a range of fields including music, film, activism, education, science, environment and technology.

To learn more about the Shawn Mendes Foundation, fans can visit www.shawnmendesfoundation.org. The sustainability Wonder Grant recipients will be announced in the coming weeks.

“It is important to me to partner with a company that values sustainability – I’m excited to partner with Chipotle and appreciate their support for my Foundation and young changemakers who are leading the charge in these crucial efforts,” said Shawn Mendes.

“We are thrilled to partner with Shawn Mendes and use the power of our real food to back the next great innovations in sustainability,” said Chris Brandt, Chief Marketing Officer. “Together with Shawn’s team and our passionate fans, we continue to pursue our mission of cultivating a better world.”

Cumulative Real Foodprint
Chipotle is also introducing a new extension of its Real Foodprint feature that will allow fans to view the cumulative potential impact of all their Chipotle orders, as compared to orders using conventional ingredients, in one comprehensive dashboard on the Chipotle app and Chipotle.com. Real Foodprint, introduced in October 2020, is a sustainability impact tracker that uses data provided by HowGood to compare average values for each of Chipotle’s real ingredients to their conventional counterparts against five (5) key metrics. 

The Real Foodprint computed for a Shawn Mendes Bowl is:

  • Less Carbon in the Atmosphere
    • 1.4 grams 
  • Gallons of Water Saved
    • 1.7 gallons
  • Improved Soil Health
    • 1.8 sq ft
  • Organic Land Supported
    • 1 sq ft
  • Antibiotics Avoided
    • 42.3 milligrams 

At the conclusion of the campaign, Chipotle will share a Real Foodprint for all Shawn Mendes bowls ordered to demonstrate the potential impact of his ingredient choices at Chipotle on the environment and animal welfare. 

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. Chipotle had over 2,700 restaurants as of September 30, 2020, in the United States, Canada, the United Kingdom, France and Germany and is the only restaurant company of its size that owns and operates all its restaurants. With more than 94,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. Steve Ells, founder and former executive chairman, first opened Chipotle with a single restaurant in Denver, Colorado in 1993. For more information or to place an order online, visit WWW.CHIPOTLE.COM.

ABOUT THE SHAWN MENDES FOUNDATION:
The Shawn Mendes Foundation seeks to inspire Shawn’s audience, the youth generation of today—to learn about those causes that they are passionate about, and help empower them to use the voice they have to bring change to the world by taking action & giving back.  As part of its ongoing mission, the Foundation provides resources and support to amplify the voices, messages, and platforms of young leaders driving positive change. SMF recently partnered with Global Citizen Year to launch the Global Citizen Academy, a first-of-its kind leadership experience for 2020 high school graduates from around the world to learn powerful and practical skills for a lifetime of social impact. Most recently, SMF provided $250,000 in need-based scholarships to ensure that tuition is not a barrier to entry and students of all economic backgrounds can participate in the Academy. The Foundation has worked with Forests Ontario to plant seven acres of trees outside of Ontario, Canada, while the SMF and Shawn have aligned with various partners in recent years across various philanthropic fields, including Pencils of Promise, VH1 Saves the Music, the Ryan Seacrest Foundation, the TJ Martell Foundation, Global Citizen, Global Changemakers, and Fridays for Future. SMF also continues its work with their primary Canadian partner, SickKids Hospital in Toronto by giving a grant to support COVID-19 testing, and will remain an active partner to provide support to the hospital through various efforts and events. The Shawn Mendes Foundation is a sponsored program of the Social Impact Fund, a 501(c)(3) charitable organization.  For information, including how to donate, please visit ShawnMendesFoundation.org.

1 For every purchase of the Shawn Mendes Bowl in the Chipotle app and on Chipotle.com between January 14, 2021 through January 28, 2021 in the US and Canada, $1 of the purchase price will go to The Shawn Mendes Foundation, a fiscally sponsored project of the Social Impact Fund. Minimum donation $10,000, and up to $50,000 USD. Visit https://www.chipotle.com/shawn to learn more.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chipotle-and-the-shawn-mendes-foundation-launch-wonder-grants-to-support-young-innovators-in-sustainability-301209090.html

SOURCE Chipotle Mexican Grill, Inc.

Posted on

Aeterna Zentaris to Present at NobleCon17

– Live video webcast with CEO, Dr. Klaus Paulini, on
Wednesday, January 20th at 12:00 PM ET –

CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) —

Aeterna Zentaris Inc.
 (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Wednesday, January 20, 2021 at 12:00 PM ET.

A high-definition, video webcast will be available at the time of the Company’s presentation to those registered to attend the event. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com.

A webcast replay will be available approximately 24 hours following the presentation on the Events page in the Investors section of the Company’s website (www.zentaris.com), and as part of a complete catalog of presentations to be rebroadcast on Channelchek, www.channelchek.com, next month.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.

Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements in this press release include those relating to Aeterna’s expectation that, upon receipt of pricing and reimbursement approvals, macimorelin will be marketed in Europe and the United Kingdom. Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, our ability to obtain receipt of pricing and reimbursement approvals as well as those risks discussed in our Annual Report on Form 20-F, under the caption “Key Information Risk Factors” filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission. Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: [email protected]



Posted on

Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

LOS ANGELES–(BUSINESS WIRE)–
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO GI) that is currently taking place. The presentation, entitled, “Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT “basket” trial,” is being presented at a Poster Session by James J. Harding, MD, Regional Director, Early Drug Development, Memorial Sloan Kettering Cancer Center, an investigator of the trial. A copy of this poster presentation is available on the Puma website.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210115005058/en/

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that included a cohort evaluating the safety and efficacy of neratinib administered daily to patients who have HER2 (ERBB2) mutation-positive advanced biliary cancer. Patients received 240 mg of neratinib daily as a single agent.

In this cohort of 25 patients, 11 patients had cholangiocarcinoma, 10 patients had cancer of the gallbladder and 4 patients had cancer of the ampulla of Vater. 24 patients had received prior systemic chemotherapy with a median of 2 prior lines of therapy (range 0-7) before entering the trial.

The efficacy results from the trial demonstrated that there were 4 patients with confirmed partial responses (3 patients with cancer of the gallbladder and 1 patient with cholangiocarcinoma) and an additional 3 patients who had stable disease lasting ≥16 weeks (1 patient with cancer of the ampulla of Vater and 2 patients with cholangiocarcinoma, one of which remained on treatment for 56 weeks before progression). This resulted in an objective response rate of 16% and a clinical benefit rate of 28%. The durations of response were 3.0 months, 3.7 months, and 4.7 months and additionally one patient with gallbladder cancer remains on treatment >80 weeks.

The safety profile of patients with biliary tract tumors is similar to that previously reported for patients treated with neratinib monotherapy and mandatory loperamide prophylaxis in the first 2 months; treatment was manageable, with 56% of patients experiencing some diarrhea, including 24% with grade 3 diarrhea. There were no episodes of grade 4 diarrhea, and no treatment discontinuations due to diarrhea. Four patients required neratinib dose reduction and one patient was hospitalized due to diarrhea.

“We have shown neratinib to be safe and tolerable in these patients with advanced biliary tract tumors, and demonstrated activity comparable to current standards of care with similar progression-free survival and overall survival in these heavily pretreated patients,” said Dr. Harding.

Alan H. Auerbach, CEO and President of Puma Biotechnology, added, “We are very pleased with the preliminary activity seen with neratinib in this cohort of patients and specifically in patients with cancer of the gallbladder and cholangiocarcinoma.”

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

  • As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

  • Diarrhea: Aggressively manage diarrhea. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction.
  • Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
  • Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS:

The most common adverse reactions (reported in ≥ 5% of patients) were as follows:

  • NERLYNX as a single agent: Diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.
  • NERLYNX in combination with capecitabine: Diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

  • Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. When patients require gastric acid reducing agents, use an H2-receptor antagonist or antacid. Separate NERLYNX by at least 3 hours with antacids. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists.
  • Strong CYP3A4 inhibitors: Avoid concomitant use.
  • Moderate CYP3A4 and P-glycoprotein (P-gp) dual inhibitors: Avoid concomitant use.
  • Strong or moderate CYP3A4 inducers: Avoid concomitant use.
  • P-glycoprotein (P-gp) substrates: Monitor for adverse reactions of narrow therapeutic agents that are P-gp substrates when used concomitantly with NERLYNX.

USE IN SPECIFIC POPULATIONS:

• Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at www.NERLYNX.com or 1-855-816-5421.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[email protected]

[email protected]

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200

[email protected]

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo